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Abstract 
Animal experiments demonstrated a significant suppressive effect of various calcium channel blockers on the 
formation of atherosclerotic lesions. Therefore, a prospective, placebo-controlled, randomized, double 
blind multicenter study was performed to investigate he inhibitory influence of the calcium channel blocker 
nifedipine (80 mg/day) on the progression of coronary artery disease in man. Study endpoints were changes 
of coronary morphology documented by coronary angiography with particular respect to the formation of
new coronary stenoses. In 348 out of 425 patients included in the study, coronary angiograms were repeated 
after three years. The angiograms were standardized by induction of a maximal coronary vasodilation with 
high doses of nitrates and by using absolutely identical angiographic projections. Quantitative analysis of 
coronary cineangiograms was performed with the computer-assisted contour detection system CAAS. 
Parameters were mean and minimal diameter of all segments and minimal stenosis diameter, percent 
diameter stenosis, length and plaque area of all stenoses. 
Continuous intake of study medication was registered in 282 patients, 134 on nifedipine and 148 patients on 
placebo. In these patients, a total of 3808 coronary segments with 893 stenoses (i> 20% diameter reduction i  at 
least one angiographic projection) were compared on the baseline and follow-up cineangiograms. The changes in
all angiographic parameters analyzed averaged over all patients by considering all angiographic projections 
analyzed, indicated significant progression of the disease (p < 0.006). The average changes in all parameters 
were even about three times more profound, when in the individual patients only the respective projections 
indicating the maximal changes were considered for the calculation (p < 0.001). However, with neither of these 
two analysis modes, the differences in progression between the treatment groups were statistically significant. 
In the follow-up angiograms, a total of 196 new coronary lesions (185 stenoses, 11 occlusions) were found 
at previously normal arterial sites. In patients on nifedipine, an average of only 0.58 new lesions per patient 
were detected versus 0,80 lesions per patient on placebo ( -  27%; p = 0.031). 
INTACT is the first prospective angiographic trial on the progression of coronary artery disease using 
computer-assisted quantitative coronary angiography in such a high number of patients. All parameters 
analyzed indicated significant progression of coronary artery sclerosis. Nifedipine had no influence on the 
progression of preexisting coronary stenoses, but inhibited significantly the formation of new angiograph- 
ically recognizable sions. Further prospective coronary angiographic trials with calcium channel blockers 
using a comparably exact method are needed to confirm the results of this study. 
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Introduction 
Studies on the long-term effects of diet or drugs on 
the progression of coronary artery disease defining 
clinical endpoints (e.g. myocardial infarction, car- 
diac death) require observation of thousands of 
patients over a period of many years [1-9]. Thanks 
to the continuous improvement in the quality of 
coronary angiograms over the past two decades, it
has become feasible to define primary angiograph- 
ic study endpoints. With such an angiographic trial 
design, the number of patients to be included can 
be reduced to a few hundred patients and the fol- 
low-up period can be limited to a few years [10-17]. 
One major problem of an angiographic determina- 
tion of the progression of coronary atherosclerosis 
is the mode of analysis of the cinefilms. Repeated 
assessment of the severity of coronary artery dis- 
ease by a panel of experienced cardiologists has 
been shown to be associated with a marked varia- 
bility [18-21]. Therefore, quantitative methods, to- 
day mostly assisted by a computer, were intro- 
duced to improve the objectivity and reproducibil- 
ity of the assessment of coronary dimensions [11, 
22-24]. With these tools, the variability of the re- 
suits of repeated measurements of coronary artery 
dimensions could be substantially reduced [24]. 
In the following, the results of the INTACT fol- 
low-up trial will be presented; in this study the 
influence of the calcium channel blocker nifedipine 
on the progression of coronary artery disease was 
studied over a period of three years. The endpoints 
of the study were defined by changes in anglo- 
graphic parameters, which were analyzed with the 
computer-assisted contot~ detection system CAAS 
(Coronary Angiography Analysis System) [23-26]. 
INTACT - International Nifedipine Trial on Anti- 
atherosclerotic Therapy - was initiated, after ani- 
mal experiments had suggested an inhibitory effect 
of various calcium channel blockers on the forma- 
tion of early atherosclerotic lesions caused by an 
atherogenic diet [27-30]. Therefore, in INTACT, 
particular attention was directed to the detection of 
newly formed coronary stenoses in the follow-up 
angiograms. 
Study design 
INTACT is a prospective, placebo-controlled, ran- 
domized, double blind, international multicenter 
study. From November 1983 to June 1985, a total of 
425 patients with preferably early stages of coro- 
nary artery disease were included in six hospitals in 
the Federal Republic of Germany and in three 
hospitals in The Netherlands. Two hundred and 
fourteen patients were randomized to nifedipine, 
211 to placebo. Inclusion and exclusion criteria of 
the study have been published in detail [31-36]. 
Inclusion of patients with previous coronary angio- 
plasty or single bypass graft implantation was al- 
lowed. Main emphasis was focussed on the pres- 
ence of numerous angiographically normal coro- 
nary segments. In all patients, high quality angio- 
grams with multiple projections of the left and right 
coronary arteries were mandatory. Number and 
angles of the angiographic projections were the 
responsibility of the individual centers; they also 
decided, whether the film quality was sufficient to 
include a patient in the study. Therefore, the num- 
ber of projections being qualified for quantitative 
analysis varied among the individual films and 
among the centers [32]. 
The rotations and angulations ofall angiographic 
projections used were noted in a special protocol. 
After the three-years-treatment p riod, a follow- 
up angiogram with the same angiographic projec- 
tions as on the baseline angiogram concluded the 
study. In order to eliminate potential coronary 
spasm and to induce profound coronary dilation, 
10 mg isosorbide dinitrate were administered 10 
minutes prior to all angiograms [37, 38]. To avoid 
influences from other vasodilating drugs, any vaso- 
active substances (incl. nifedipine) except nitro- 
glycerin administered sublingualty were withheld 
two days before angiography. All angiographic and 
clinical baseline data (number of coronary stenoses 
and occlusions, coronary risk factors, previous 
myocardial infarctions, previous PTCA, angina 
pectoris etc.) were not different between the two 
treatment groups (for details ee 35, 36). 
Analysis' of cinefilms 
The angiograms were evaluated either in Hannov- 
er or in Rotterdam using identical CAAS systems 
[23-26]. At the beginning of each fihn analysis, two 
experienced cardiologists, who were unaware of 
the patient's drug regimen, selected appropriate 
projections, cineframes and coronary segments us- 
ing standard Tagarno cinefilm projectors. Paired 
films were viewed side by side to optimize cine- 
frame selection. Based on the recommendations of 
the American Heart Association, the coronary ar- 
tery tree was subdivided into 15 different segments 
[39]. To consider anatomic variants, an additional 
10 segments were defined [32, 33, 38]. Selection 
criteria for the segments included: 1) major por- 
tions of the segments hould run parallel to the 
image plane without considerable overlaps with 
other radio-opaque structures; and 2) segments 
should be maximally stretched, preferably in the 
end-diastolic phase of the cardiac cycle. Occluded 
segments, as well as segments located distal to oc- 
clusions although still opacified via collaterals, and 
segments of grafted arteries were not analyzed. 
Segments with previous angioplasty were mea- 
sured, but these data will be analyzed separately. 
The arrangement and contour detection algo- 
rithm of the CAAS system have been described in 
detail [23-25]. Following twofold optical magnifi- 
cation and conversion into video format with the 
help of a specially developed cine-video-converter 
(CIVICO II), regions of interest in the frames were 
digitized (12 x 512 x 8 bits) and stored in image 
memory for subsequent image processing on a PDP 
11/24 (Hannover) or PDP 11/44 (Rotterdam) com- 
puter system. Calibration of the frames was per- 
formed on the basis of the tip or shaft of the 8F- 
coronary contrast catheters which had been mea- 
sured with a precision mechanical caliper immedi- 
ately following angiography. At the beginning of 
each angiographic sequence, the tip and shaft of 
the coronary catheters had been filmed without 
contrast filling close to the image center. For cali- 
bration purposes the region of interest encompass- 
ing the catheter segment was magnified optically by 
a factor of 2V~.  Pin-cushion distortion of all image 
intensifiers involved in the study was documented 
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by filming a centimeter grid. All these frames were 
processed with a special algorithm and the corre- 
sponding correction vectors tored on the CAAS 
systems [23]. At the time of analysis of a coronary 
angiogram from a particular catheterization lab- 
oratory, the corresponding correction factors 
would be retrieved and applied to the detected 
contours of the catheter and the coronary seg- 
ments. 
The arterial contour detection algorithm of 
CAAS has been published extensively and will not 
be described here [23, 25]. Of each segment, the 
mean diameter was computed on the basis of dia- 
meter measurements taken at increments of about 
0.1 mm along the segment's center line [23]. The 
presence of a coronary stenosis was suggested by 
the cardiologist who inspected the film; this deci- 
sion was verified with a special algorithm identify- 
ing the site of the minimal stenosis diameter. A 
narrowing in a segment was defined as being a 
stenosis, if the diameter eduction exceeded 20% 
in at least one angiographic view. This 20% thresh- 
old corresponds to about the threefold standard 
deviation of the differences in the determination f
percent diameter stenosis in different cineframes 
[23, 25]. The actual percent diameter stenosis was 
computed by comparing the minimal obstruction 
diameter with the interpolated reference diameter 
value taken at the same location and derived from 
the reference diameter function. This reference 
diameter function is a best approximation of the 
original size of the vessel before disease occurred 
and is computed on the basis of the diameters of 
'normal' adjacent subsegments (23; Fig. 1). In ad- 
dition, the algorithm provided data about the 
length of the stenosis, as well as the 'plaque area'; 
the area of the atherosclerotic plaque equals the 
area between the luminal and the reconstructed 
reference contours as measured over the obstruc- 
tive region (Fig. 1). Data about the mean differ- 
ences (accuracy) and the standard eviations (pre- 
cision) of the differences of repeated measure- 
ments as assessed with the CAAS have been de- 
scribed elsewhere [23]. 
The INTACT protocol defines the following an- 
giographic study endpoints: increase or decrease in
the average and minimal diameter of a complete 
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Fig. 1. Example of a CAAS-analysis of an obstructed proximal 
segment of the left anterior descending artery; R = reference 
diameter function; B = stenosis boundaries marking its length; 
P = plaque area. 
coronary segment, or in the minimal stenosis dia- 
meter, in percent diameter stenosis, in stenosis 
length or plaque area of preexisting stenoses, as 
well as stenosis progression to total occlusion. 
Based on the known variability of the method in 
quantitating stenosis parameters in repeated angio- 
grams [23, 25], a change in the minimal stenosis 
diameter of 0.4 mm (twofold standard eviation of 
the method) or more, or in the percent diameter 
stenosis of I> 20% (threefold standard eviation of 
the method) was defined as definite progression or 
regression of the narrowing. Formation of new ste- 
noses (percent diameter stenosis 1> 20%) or occlu- 
sions at sites previously free from angiographically 
recognizable narrowings (% diameter stenosis 
<20%) as measured by the computer algorithm 
was the primary end-point of progression. When 
new stenoses were detected in the second angio- 
gram, the identical segment was always reanalyzed 
in the first angiogram to assure that no stenosis had 
been overseen. The average percent diameter ste- 
nosis of the new stenoses was 40% indicating that 
most new stenoses had undergone an increase of at 
least 20%. 
In INTACT, most segments and stenoses were 
analyzed in more than one angiographic projection 
per patient (two projections on the average); that 
means, that he degree of change in an angiograph- 
ic segment parameter o in a stenosis parameter of
an individual patient could depend on the projec- 
tions which were considered. One way to minimize 
this projection dependency is to average the chang- 
es of a parameter over all projections in which it 
was analyzed in the individual patient. Another 
possibility would be to select only one projection 
from the available set which shows the largest in- 
crease or decrease ina particular parameter. Table 
1 makes clear that he projections with the maximal 
increases or decreases in absolute diameter mea- 
surements ofthe coronary segments orthe obstruc- 
tions show the maximal regression and progres- 
sion, respectively, whereas the opposite is true for 
the relative percent stenosis and the derived par- 
ameters length of stenosis and area plaque. 
Table 1. The definition of progression or regression depends very much on the parameters and the changes in these parameters studied. 
For example, maximal increases or decreases in absolute diameter values of the coronary segments represent maximal regression or 
progression, respectively. Inversely, maximal increases or decreases in the relative percent diameter stenosis or derived length or area 
plaque parameters epresent maximal progression or regression, respectively. 
Projection Maximal progression Maximal regression 
(minimal regression) (minimal progression) 
Maximal increase 
(minimal decrease) 
Maximal decrease 
(minimal increase) 
percent stenosis 
length of stenosis 
area plaque 
mean segment diameter 
rain, segment diameter 
min. stenosis diameter 
mean segment diameter 
min. segment diameter 
min. stenosis diameter 
percent stenosis 
length of stenosis 
area plaque 
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Statistics 
An inhibitory effect of nifedipine on the formation 
of atherosclerotic lesions has been demonstrated in 
numerous animal experiments [27, 29, 30]. The 
objective of INTACT was to test the null hypothe- 
sis, that nifedipine does not inhibit the progression 
of coronary atherosclerosis in man, i.e., the pro- 
gression of preexisting coronary stenoses (increase 
of percent diameter stenosis, length or area plaque; 
decrease of diameter), as well as particularly the 
formation of new stenoses. Therefore, one-sided 
statistical tests were applied, when comparing the 
progression of preexisting coronary stenoses and 
the formation of new lesions between the two study 
groups. In all other comparisons, two-sided tests 
were used. For binary variables, the Chi square test 
was used. For discrete ordered variables with a 
small number of categories, Cochran's test for line- 
ar trend was applied. Other variables were ana- 
lyzed with the Student -test, using the separate 
variance stimation, if necessary. If more than one 
observation was contributed by one patient, the 
mixed model analysis of variance was used. 
Results 
Of the 425 patients included in the study, 282 pa- 
tients, 148 on placebo (P) and 134 on nifedipine 
(N), completed the study without relevant protocol 
violations. Protocol violations comprised termina- 
tion of participation i the study or of drug intake, 
reduction or temporary stop of drug intake and 
intake of additional caldum channel blockers. 
Reasons for protocol violations were side effects, 
critical events, refusal or need for calcium block- 
ers. Side effects of the drugs were registered in 71 
patients, in 16 patients on Placebo and in 55 pa- 
tients on Nifedipine (p = 0.003). In the patients on 
Nifedipine, headache, dizziness, flush, and ankle 
edema were the mostly reported side effects. In 
either treatment group, angina pectoris ymptoms 
were slightly reduced uring the study. For further 
informations on protocol violations and clinical fol- 
low-up see references [31, 34-36]. 
In the 282 patients without protocol violations 
(group I), the interval between the two study an- 
giograms averaged 1123 + 55 days (N) and 1122 + 
47 days (P), respectively. In addition, 66 patients 
(39 on N, 27 on P) with major protocol violations 
underwent two angiograms after an average in- 
terval of 992 + 262 days (N) and 918 ___ 317 days 
(P), respectively (group II). These patients top- 
ped the intake of study medication after an average 
interval of 359 + 237 days (N) and 467 + 270 days 
(P), respectively. The remaining 77 patients, 41 on 
N and 36 on P, were lost for angiographic follow-up. 
Table2. Number of segments and lesions (stenoses and occlusions) measured inthe first and second angiograms of the patients of groups 
I and II. 
Segments Segment measurements Proj./segment Lesions 
Group I
1. Angio 3916 (13.9/pt) 7950 (28.3/pt) 2.0 
2. Angio 3808 (13.5/pt) 7570 (26.8/pt) 2.0 
108 lost 420 lost 
Group II 
1. Anglo 929 (14.1/pt) 1847 (28.0/pt) 2.0 
2. Angio 880 (13.3/pt) 1700 (25.8/pt) 1.9 
49 lost 147 lost 
Group I + group II 
1. Angio 4845 (13.9/pt) 9837 (28.3/pt) 2.0 
2. Anglo 4688 (13.5/pt) 9270 (26.6/pt) 2.0 
157 lost 567 lost 
PT = patient; Proj. = number of projections. 
1072 (3.8/pt) 
1230 (4.4/pt) 
38 lost; 196 new 
183 (2.8/pt) 
225 (3.4/pt) 
9 lost; 51 new 
1255 (3,6/pt) 
1455 (4.2/pt) 
47 lost; 247 new 
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Fig. 2. Average number of coronary lesions (stenoses and occlu- 
sions) per patient in the inclusion angiograms of patients on 
nifedipine (N) and on placebo (P) and distribution oflesions 
among the three major coronary arteries; LM = left main ar- 
tery; LAD- left anterior descending artery; LCX = left cir- 
cumflex artery; RCA = right coronary artery; (N vs P: separate 
variance analysis). 
In the 348 patients with two study angiograms 
each (groups I and II), a total of 4688 different 
segments (13.5 per patient) were compared be- 
tween the two study angiograms (Table 2). Since 
the segments were measured in an average of 2.0 
different (mostly nearly orthogonal) angiographic 
projections, a total of 9270 segment measurements 
from the inclusion angiograms were repeated at 
follow-up. Due to poor quality of the follow-up 
angiograms or to occlusions of previously patent 
segments, 157 segments and 567 segment measure- 
ments from the inclusion angiograms were lost for 
follow-up (Table 2). 
A total of 1255 coronary lesions (an average of 
3.6 per patient), i.e. 1105 stenoses and 150 occlu- 
sions, were detected in the inclusion angiograms 
(Table 2). Twenty stenoses were lost for follow-up 
due to poor film quality, another 27 due to new 
occlusions at sites located proximal to the known 
stenoses, i.e., a total 0f47 stenoses were lost. Since 
247 new lesions, 228 stenoses and 19 occlusions 
were found in the follow-up angiograms, a total of 
1455 lesions (4.2 per patient) were finally analyzed 
(Table 2). 
The following analysis of angiographic baseline- 
and follow-up data will concentrate on the results 
of the 282 patients without relevant protocol vio- 
lations (group I). In the patients on N, an average 
of 3.7 lesions per patient (438 stenoses and 60 oc- 
clusions) were found in the inclusion angiograms 
versus 3.9 lesions per patient on P (507 stenoses 
and 67 occlusions) (n.s.). The distribution of the 
lesions among the three major coronary arteries is 
demonstrated in Fig. 2. In either group, the right 
coronary artery (RCA) presented more lesions 
when compared with the left anterior descending 
(LAD; p < 0.001) and left circumflex artery (LCX; 
p < 0.05), the differences between the study groups 
not being significant. 
The changes in the parameters of all 3808 seg- 
ments and the 945 preexisting stenoses analyzed in 
the group-I-patients over the study period of 3 
years are presented in Table 3. For both treatment 
groups, the changes in the parameters were aver- 
aged in two ways: 1) from the individual mean 
values computed from the changes in all projec- 
tions in which the parameters were analyzed in a 
patient; and 2) from the individual projections 
showing the greatest changes in the respective seg- 
ment or stenosis parameters in the sense of pro- 
gression of the disease. Segments and stenoses 
changing to occlusions were excluded in this analy- 
sis (see Table 1). In all parameters, the changes 
indicated progression of coronary artery disease 
(p < 0.006). However, when only the projections 
demonstrating the maximal change in a parameter 
in the sense of progression were considered, the 
changes were about hree times greater in compari- 
son to the average changes over all projections 
analyzed (Table 3). It is of particular relevance that 
- independent ofany consideration fangiographic 
projections - no significant differences were ob- 
served between the treatment groups in the chang- 
es of any of the parameters. 
Another mode of analysis of the progression or 
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Table 3. Average changes in the angiographic parameters of 3808 segments and 893 stenoses (N = 404, P = 489) 1 between the two study 
angiograms in either study group according to two different modes of consideration f projections% 
Parameters Mean change over projections 
N P 
Maximal progression over projections p p 
(1. vs 2. (N vs P) 
N P angiogram) 
Mean segment -0 ,03+ 0.32 -0 .03+ 0.29 -0 .15+ 0.35 -0 .14+ 0.32 <0.006 n.s. 
diameter (rnm) 
Min. segment -0.05 + 0.33 - 0.05 + 0.31 - 0.18 + 0.37 -0 .19+ 0.35 <0.001 n.s. 
diameter ( am) 
Min. stenosis - 0.05 + 0.32 - 0.07 + 0.35 - 0.15 + 0.35 - 0.17 + 0.40 < 0.001 n.s. 
diameter (mm) 
Percent diameter +2.78+ 12.4 +2.36+ 13.0 +7.62+ 15.7 +6.81+ 15.2 <0.001 n,s. 
stenosis (%) 
Length of stenosis + 0.51+ 1.91 + 0.47 + 1.81 + 1.28 + 2.46 + 1.30 + 2.47 <0.001 n.s. 
(ram) 
Area plaque + 0.71 + 3.23 + 0.61 + 3.37 + 1.91 + 4.09 + 1.77 + 3.99 < 0.001 n.s. 
(ram x mm) 
Stenoses changing 9 9 9 9 n.s. 
to occlusions 
N = nifedipine; P = placebo. 
1 Fifty-two stenoses ofthe inclusion angiograms were excluded: 38 stenoses were lost, 18 changed to occlusions (4 occlusions recanatized 
to stenoses). 
2 Except preexisting occlusions and changes of stenoses to occlusions. 
regression of the stenoses in group I-patients is 
demonstrated in Tables 4 and 5. In this case, only a 
change in the minimal stenosis diameter exceeding 
+ 0.4 mm or in percent diameter stenosis exceed- 
ing + 20% was regarded as definite stenosis pro- 
gression or regression; stenoses changing to occlu- 
sions were excluded. When the mean changes of all 
projections analyzed in the individual patients 
were considered, 8-15% of the stenoses of either 
group showed progression, and 3-7% showed re- 
gression (N vs P: n.s.; Table 4). When only the 
projections indicating the maximal progression or 
Table 4. Progression and regression 1 of 404 preexisting stenoses in 134 patients on N and of 489 stenoses in 148 patients on pz. 
No. of stenoses 
Mean change over projections Maximal progression/regression overprojections 
N P N P P 
(N vs P) 
Change in minimal 
stenosis diameter 
Progression (decrease) 43 (10.6%) 74 (15.1%) 77 (19.1%) 120 (24,5%) n.s. 
Regression (increase) 24 (5.9%) 35 (7.2%) 52 (12.9%) 66 (13.5%) n.s. 
Change in percent 
diameter stenosis 
Progression (increase) 38 (9.4%) 38 (7.8%) 71 (17.6%) 78 (15.9%) n.s. 
Regression (decrease) 14 (3.5%) 24 (4.9%) 25 (6.2%) 44 (9.0%) n.s, 
1 Progression/regression of stenosis = change in minimal stenosis diameter exceeding _+0.4 mm or exceeding percent diameter stenosis 
in + 20%. z Except preexisting occlusions and changes of stenoses to occlusions. 
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regression of a stenosis were considered, progres- 
sion as well as regression were more frequent with 
16-24% and 6-13% of stenoses, respectively (N vs 
P: n.s.; Table 4). 
According to the same two modes of definition 
of stenosis progression or regression (change in 
stenosis diameter exceeding + 0.4mm or in per- 
cent diameter stenosis exceeding +20%), the 
groups of patients with at least one stenosis reveal- 
ing progression or regression were analyzed (ex- 
cluding stenoses changing to occlusions) (Table 5). 
When the mean changes over all projections ana- 
lyzed in the individual patients were considered, 
progression was observed in 19-32% of the pa- 
tients, regression i  10-21% of the patients and the 
combination of both in 2-4% of the patients (N vs 
P: n.s.). Again, progression and regression were 
observed more frequently when only the projec- 
tions demonstrating the maximal progression or 
regression were taken into account (Table 5; N vs 
P: n.s.). 
In the follow-up angiograms of the 282 patients 
of group I, a total of 196 new lesions (185 stenoses 
and t l  occlusions) were detected at arterial sites 
previously defined as normal. In 54 out of the 134 
patients on N (40%), 72 new stenoses and 6 occlu- 
sions were found versus 113 new stenoses and 5 
occlusions in 73 out of the 148 patients on P (49%; 
n.s.), i.e. an average of 0.58 lesions per patient on 
N versus 0.8 lesions per patient on P ( -  27%; p = 
0.031; Fig. 3). When the distributions of the new 
lesions in the three major coronary arteries were 
analyzed with respect to the two treatment groups, 
a significant difference between the N- and P-group 
was observed in the LAD (0.13 lesions per patient 
on N versus 0.22 lesions per patient on P; - 40%; 
p = 0.047) and the LCX (0.16 versus 0.26 lesions 
per patient; - 38%; p = 0.035). In the RCA, the 
vessel with the highest number of preexisting le- 
sions, the highest number of newly formed lesions 
was detected. However, in this artery the differ- 
ence between the treatment groups was not statisti- 
cally significant (0.27 versus 0.29 lesions per pa- 
tient; -8%;  p = 0.38). (Fig. 3). 
When all 348 patients with and without protocol 
violations who underwent two study angiograms, 
were considered in the analysis of data, again no 
significant differences were found between the two 
study groups with regard to changes in preexisting 
lesions [35]. The significant difference between the 
two treatment groups in the number of new lesions 
per patient, however, was confirmed by this 'in- 
Table 5. Number of patients with at least one stenosis undergoing definite progression or regression 1. 
No. of patients 
Mean change over projections Maximal progression/regression overprojections 
N P N P P 
(n= 134) (n= 148) (n= 134) (n= 148) (NvsP) 
Change in minimal 
stenosis diameter 
Progression (decrease) 33 (25%) 47 (32%) 54 (40%) 60 (41%) n.s. 
Regression (increase) 22 (16%) 31 (21%) 42 (32%) 49 (33%) n.s. 
Progression+ regression 6 (4%) 6 (4%) 2 8 (6%) 10 (7%) 2 n.s. 
no change 85 (63%) 76 (51%) 46 (34%) 49 (33%) n.s. 
Change in percent 
diameter stenosis 
Progression (increase) 30 (22%) 28 (19%) 53 (40%) 46 (31%) n.s. 
Regression (decrease) 13 (10%) 22 (15%) 22 (16%) 36 (24%) n.s. 
Progression + regression 3 (2%) 3 (2%) z 4 (3%) 5 (3%) n.s. 
no change 94 (70%) 101 (68%) 63 (47%) 71 (48%) n.s. 
For definitions see Table 4; stenoses changing to occlusions are excluded. 
2 Patients with both regression and progression are also listed among the patients with progression orregression. 
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Fig. 3. Average number of new coronary lesions per patient 
detected in the follow-up angiograms of the 282 patients without 
protocol violations (group I) and distribution among the three 
major coronary arteries (abbreviations see Fig. 1). (Cochran's 
test for linear trend). 
tention to treat' evaluation mode. Of 247 newly 
formed lesions, 228 stenoses and 19 occlusions, 103 
were detected in the N-group and 144 in the P- 
group corresponding to an average of 0.59 new 
lesions per patient on N and of 0.82 lesions per 
patient on P ( -  28% ; p -= 0.017; Fig. 4). 
During the study period coronary risk factors 
such as smoking or arterial hypertension had di- 
minished significantly in patients of either treat- 
ment group, the differences between the groups 
being not significant. Total cholesterol levels re- 
mained unchanged in either group [35, 36]. 
Discussion 
Since the end of the nineteen seventies, experi- 
ments have been performed with rabbits fed with 
an atherogenic diet which demonstrated an inhi- 
bition of the development of aortic atherosclerotic 
lesions with various calcium channel blockers [27- 
30]. In most of these experiments, the drugs were 
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Fig. 4. Average number of new coronary lesions per patient in 
all 348 patients with two angiograms (groups I and II) (Co- 
chran's test for linear trend). 
administered in doses much higher than those tol- 
erated by man [2%29]. Only nifedipine proved to 
inhibit he formation of atherosclerotic lesions in a 
dosage which can be administered in man - 0.1 mg/ 
kg bodyweight given orally [30]. Therefore, the 
identical drug regimen was applied in the INTACT 
study. In the rabbit model, the calcium channel 
blockers were demonstrated to inhibit the devel- 
opment of early atherosclerotic cholesterol-rich le-
sions [2%30]. Consequently, in INTACT the main 
emphasis was focussed on the influence of nifedi- 
pine on the formation of new stenoses. Nonethe- 
less, the changes in preexisting stenoses were of 
great interest and were analyzed as well. However, 
progression of stenoses to occlusions was analyzed 
separately, since it represents a consequence of
thrombosis rather than of atherosclerosis. 
There is one major limitation in angiographic 
studies in general, being that only such changes in 
the coronary arterial wall can be documented and 
measured which result in a reduction in the dia- 
meter of the vessel lumen. In INTACT, atheroscte- 
rotic lesions which did not cause a diameter reduc- 
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tion of at least 20% in at least one angiographic 
projection in the baseline angiograms were ne- 
glected. This 'threshold' was selected with respect 
to the limited accuracy of coronary angiography in
general [40, 41] and to the known variability in 
repeated analyses of angiograms with the CAAS 
system in particular [23, 25]. 
The results of INTACT suggest an effect of nife- 
dipine on the development of atherosclerotic le- 
sions in man similar to that observed in animals. 
The effects on new coronary lesions were not only 
observed in patients who took the drug over the 
entire period of three years, but also in patients 
treated for only about one year on average. The 
suppression ofthe formation of new lesions in these 
patients underlines the antiatherosclerotic poten- 
tial of the calcium channel blocker, although this 
collective was rather small. Therefore, when the 
data were analyzed according to the 'intention to 
treat' principle, the drug effects became ven more 
apparent. It is of particular importance to mention 
that the risk factor profiles before and during the 
study were not different between the two treat- 
ment groups and could, therefore, not contribute 
to the differences in the progression of coronary 
sclerosis [35, 36]. 
The inhibitory effect of nifedipine on the devel- 
opment of new atherosclerotic lesions was limited 
to the LAD and LCX artery and was not observed 
in the RCA. One reason for this observation may 
be that already in the inclusion angiograms, the 
RCA presented the highest number of preexisting 
lesions, i.e. with the most advanced atherosclero- 
sis. Less 'normal' coronary segments could mean 
less targets for the protective ffect of nifedipine. 
The number of newly formed lesions was also high- 
est in the RCA as already observed in previous 
studies [42-44]. One explanation may be that blood 
flow which has been shown to be different between 
the three large coronary arteries, could play a role 
in the development and progression of coronary 
atherosclerosis [45, 46]. 
To date, there is only one study on the effect of a 
calcium channel blocker on the progression of cor- 
onary atherosclerosis in man which may be compa- 
rable to INTACT [17]. Using a retrospective film 
analysis, the authors found a significant inhibition 
of the formation of new coronary stenoses in pa- 
tients treated with the dihydropyridine nicardi- 
pine. As in our study on nifedipine, preexisting 
coronary stenoses were not influenced by nicardi- 
pine [17]. In another study, comparing the effects 
of nifedipine on coronary atherosclerosis with 
those of isosorbide dinitrate and propranolol, the 
calcium channel blocker was demonstrated to in- 
hibit the formation of new lesions as well as the 
progression of preexisting stenoses [47]. However, 
this study did not use a randomized and double 
blind protocol. 
It is a limitation of many previously published 
angiographic studies on the progression of coro- 
nary artery disease, that the main interest was fo- 
cussed upon preexisting stenoses rather than on the 
formation of new angiographically recognizable - 
sions [12-14, 43, 44, 48-53]. This is a point of ex- 
traordinary interest, since interventions which may 
influence the formation of early lesions, e.g. by an 
effect on the cholesterol uptake into the vascular 
endothelium, do not necessarily influence the pro- 
gression of preexisting stenoses. Today, progres- 
sion of already established stenoses i regarded to 
be associated with adhesion of platelets which ex- 
crete potent issue growth factors provoking prolif- 
eration of smooth muscle cells and connective tis- 
sue, i.e. growth of the plaque [54]. In animal ex- 
periments, the mere presence of a stenosis proved 
to be sufficient o provoke platelet adhesion [55]. 
Plaque rupture with consecutive thrombus forma- 
tion, as documented in patients with unstable angi- 
na or myocardial infarction, may play an additional 
role in the progression of preexisting stenoses [56, 
57]. Hence, mechanisms for the formation of new 
lesions on the one hand and for the progression of 
established lesions on the other hand may be differ- 
ent. 
In some INTACT-patients with multiple preex- 
isting stenoses, progression as well as regression 
was observed. That means that different stenoses 
in the identical patient were subject o contrary 
developments in spite of a common exposition to 
coronary risk factors as nicotine, cholesterol, hy- 
pertension, etc. or to a potentially protective sub- 
stance as nifedipine. Therefore, other factors may 
additionally influence the progression and regres- 
sion of preexisting lesions, as for instance, the loca- 
tion of a stenosis with regard to bends or ram- 
ifications, or the shape, i.e. the taper of the surface 
of a stenosis [46]. 
In INTACT, the average changes in the anglo- 
graphic parameters of the preexisting stenoses 
were relatively small when compared to similar 
investigations [58]. In addition, only about 40% of 
the patients revealed definite progression of at 
least one stenosis, when changes of more than 
0.4 mm in stenosis diameter or of more than 20% in 
stenosis severity were defined as progression or 
regression. This indicates a much lower progres- 
sion rate than found in previous tudies which usu- 
ally defined stenosis progression as an increase in 
percent stenosis by at least 20% as assessed by 
visual film inspection [10, 42, 43, 50, 59, 60]. One 
reason may be that - in contrast to INTACT- these 
studies mainly selected symptomatic patients in a 
retrospective mode. In addition, in contrast to 
most of these previous tudies, patients with mod- 
erate coronary atherosclerosis were preferably in- 
cluded in INTACT. 
Except for INTACT, only one angiographic fol- 
low-up study has been performed in which coro- 
nary angiograms were repeated in exactly identical 
projections [15]. However, in this study, progres- 
sion of coronary artery disease was assessed by 
visual inspection. It has been shown that only by 
observation of absolutely identical angiographic 
projections, major errors emerging from even 
slightly different views can be circumvented [61]. 
In the present study, coronary segments were 
analyzed quantitatively in an average of as many as 
two different (mostly nearly orthogonal) angio- 
graphic projections. Therefore, the calculation of a 
mean change over all projections performed was 
possible on the one hand, and a selection of the 
projection with the most profound change on the 
other hand. When only the projections with the 
most profound changes in the sense of progression 
were considered, the average progression of all 
parameters was substantially greater when com- 
pared to the calculation of average changes over all 
projections. The same difference was found, when 
the number of definitely progressive stenoses and 
of patients with such stenoses were compared. It 
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should be considered, however, that, when only 
the projection indicating the maximal progression 
is taken into the calculation, most of the errors of 
the method which result in an overestimation of
progression may be selected, and most of the errors 
resulting in an underestimation f progression may 
be neglected. That means that this mode of eval- 
uation can result in an overestimation f the true 
progression of coronary artery disease. On the 
other hand, information is lost when the changes 
are averaged over all projections. Calculation of 
the percent area stenosis, i.e. of the percentage 
reduction in the vessel's cross section by the athe- 
rosclerotic plaque, would be the perfect solution. 
However, percent area stenosis cannot be mea- 
sured reliably with contour detection systems. 
Even when multiple views are available, the area 
stenosis of 'complicated' stenoses, i.e. of stenoses 
with an asymmetric lumen, is difficult o assess with 
this method [61, 62]. Therefore, the observation of 
numerous angiographic projections and consider- 
ation of the projection with the maximal change 
seems to be the most appropriate mode to assess 
progression (or regression) of coronary atheroscle- 
rosis with an edge detection system as CAAS. One 
alternative available today is cine-video-densitom- 
etry which is supposed to measure the percent area 
stenosis from only one view. However, there are 
still many methodologic problems in cine-video- 
densitometry which shall not be discussed here [63- 
66]. 
The goal of INTACT was to test, whether pro- 
gression of coronary artery disease can be slowed 
down with nifedipine. Regression was not a pri- 
mary endpoint, but was observed in some patients. 
It is still a subject of discussion, whether 'regres- 
sion' in the sense of reduction of a manifest plaque 
is really possible [67-70]. Angiographically proven 
reduction of percent stenosis or increase in stenosis 
diameter does not necessarily mean reduction of 
the plaque. The media of atherosclerotic arterial 
segments i known to become thinner, resulting in 
dilation of the vessel lumen; this may pretend 're- 
gression' [71-73]. Furthermore, thrombus adhe- 
sion to a stenosis in one angiogram might have 
disappeared in the next one imposing as 'regres- 
sion'. In future studies with intracoronary echoar- 
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teriography or with magnetic resonance imaging 
(MRI), it might be possible to determine the true 
plaque dimensions [74-76]. That means that differ- 
entiation between actual plaque regression and 
'pseudo regression' could be possible. In addition, 
it could be possible to perform amore sophisticated 
analysis of plaque growth and composition with 
intracoronary echoarteriography. 
INTACT is the first angiographic follow-up 
study in which strict attempts were made to create a
comparable, i.e. a standardized coronary vasomo- 
tor tone. This was achieved by administration f a 
high dose of isosorbide dinitrate which induces 
nearly maximal coronary vasodilation [37]. Influ- 
ences of other vasoactive substances were avoided, 
since they were withheld two days before angiogra- 
phy. The variability of the coronary vasomotor 
tone has not been considered inprevious investiga- 
tions of the reproducibility of the assessment of
coronary dimensions with the CAAS system in the 
same patients after an interval of days or months 
[23]. When in similar investigations with the CAAS 
system coronary vasodilation had been induced 
prior to repeated angiograms, the standard evia- 
tion values of the mean differences between the 
measurements were found to be considerably low- 
er [23]. Based on these data, a stenosis was arbitra- 
rily defined by a diameter reduction of at least 20% 
(approx. threefold standard eviation). In addi- 
tion, the threshold for definite progression and 
regression of coronary artery disease was fixed at a 
percent diameter stenosis of 20% and at a stenosis 
diameter of 0.4 mm (approx. twofold standard e- 
viation). The definition of a stenosis as diameter 
reduction of as much as at least 20% might have led 
to a drop-out of true (i.e. falsely negative) stenoses 
caused by an atherosclerotic plaque. However, this 
high threshold has prevented the inclusion of too 
many stenosis artifacts (i.e. falsely positive stenos- 
es) in the data bank. 
Some of the angiographic stenosis parameters 
analyzed in INTACT, e.g. interpolated percent 
diameter stenosis and plaque area, depend on the 
assumption of 'normal' adjacent subsegments, a 
precondition which is not always realized. None- 
theless, in both treatment groups these parameters 
indicated the progression of coronary artery dis- 
ease to a similar degree as did the diameter mea- 
surements. In previous studies, absolute param- 
eters were shown to indicate the progression of 
coronary artery disease more reliably than derived 
parameters [58]. Anyhow, in INTACT a stenosis 
was not defined as absolute change in the arterial 
diameter - for example of at least 0.4mm - but in 
percentage diameter reduction of at least 20%. The 
reason was that in segments with diameters anging 
from 1 mm to 6 mm - as in INTACT - a diameter 
reduction of for instance 0.4 mm would correspond 
with a percentage diameter eduction ranging 
widely from as little as 7% to as much as 40%. 
Maybe, the combination of either a localized ia- 
meter eduction by/> 0.4 mm and/or a percent dia- 
meter stenosis 1> 20% would be a more sensitive - 
but still arbitrary - definition of a coronary stenosis. 
In addition to the 15 different coronary segments 
defined by the American Heart Association [39], 
analysis of 10 further segments was possible in IN- 
TACT. They were only selected in anatomic vari- 
ants (dominance of one artery). A segment dia- 
meter of i mm was the smallest that was accepted, 
since contour detection systems could not reliably 
measure smaller vessel diameters [24, 77, 78]. Due 
to the wide spectrum of segment diameters mea- 
sured in INTACT, the progression of coronary ar- 
tery disease and its modification by nifedipine can 
also be differentiated with regard to the caliber of 
the segments; this will be the subject of future analys- 
es. 
In no previous coronary angiographic studies as 
many arterial segments were quantitatively ana- 
lyzed as in INTACT [14, 58]. A number of seg- 
ments could not be reanalyzed in the follow-up 
angiograms due to occlusions of the segments 
themselves or of proximal segments. In addition, 
data of few segments and stenoses were lost in the 
follow-up angiograms due to poor film quality. 
Nonetheless, the high number of an average of 13.5 
different segments per patient compared between 
the angiograms proves that quantitative analysis of 
repeated coronary angiograms i  highly reproduc- 
ible when identical projections are compared. 
Despite the relatively objective method to ana- 
lyze contours of coronary segments with an auto- 
mated system, there were numerous ubjective 
moments in the comparison of repeated coronary 
angiograms in INTACT. The selection of appropri- 
ate segments, projections, and film frames had to 
be done by an experienced specialist; so far, no 
algorithm is able to make these decisions. Some- 
times, manual contour corrections were necessary 
in the presence of ramifications of segments or of 
short overlaps; so far, these pitfalls cannot be rec- 
ognized by an algorithm. In addition, new stenoses 
had to be detected primarily by the investigator 
who had the task to identify the stenoses, even 
when hidden in ramifications or behind overlaps, 
i.e. when visible in only one or few frames. Arti- 
facts, e.g. caused by muscle bridges, temporary 
lack of contrast or in bends had to be differentiated 
from (probably) truly atherosclerotic lesions. The 
stenoses uggested by the analyzer had to be ver- 
ified with the automated measurement. I  is likely 
that a number of true stenoses have been missed in 
INTACT and that the subjective criteria men- 
tioned above led to errors. However, these errors 
would be distributed similarly among the study 
groups and, therefore, can not influence the con- 
clusiveness of the study results. 
The following sources of error may also have 
contributed to inaccuracies in the results: 1) Cali- 
bration of the cine frames with the help of the 
coronary catheter (although actual catheter dimen- 
sions were available); 2) pincushion distortion 
(which was corrected for the most part by a special 
algorithm [23]; 3) comparison of segments not be- 
ing in absolutely identical positions in the image 
planes [25]; 4) problematic reproducibility of an 
identical inspiratory state of the patients [26, 79]; 5) 
nonlinear behaviour of the transfer function of the 
cinefilm, quantum noise of the images, electronic 
noise contributions in the analog to digital con- 
version etc. [23]. All these limitations were consid- 
ered in the variability of the method as already 
published [23]. 
The following conclusions may be drawn from 
the results and the methodologic experiences from 
INTACT: 
1. An inhibitory effect of nifedipine on the forma- 
tion of new atherosclerotic lesions in human 
coronary arteries is highly probable. Nifedipine 
seems to have no influence on the further devel- 
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opment of preexisting stenoses. Additional 
prospective coronary angiographic studies with 
calcium channel blockers hould be undertaken 
to confirm the results of INTACT. 
2. In this prospective angiographic analysis of pa- 
tients with moderate coronary artery disease, 
the progression of the disease has been shown to 
develop more slowly than demonstrated in pre- 
vious retrospective trials. 
3. In studies on interventions influencing the pro- 
gression of coronary artery disease, more atten- 
tion should be focussed on an important charac- 
teristic of progression - the formation of new 
atherosclerotic lesions. 
4. Elimination of a variable coronary vasomotor 
tone with vasodilating agents and comparison of 
absolutely identical angiographic projections 
should be prerequisites for angiographic follow- 
up studies. 
5. In multicenter coronary angiographic follow-up 
trials, strict quality control of all angiograms 
should take place in the core center of film anal- 
ysis before inclusion of any patient into the 
study. This could allow for opportune rejection 
of films with suboptimal quality and could lead 
to analysis of even more segments in more an- 
giographic projections than in INTACT. 
6. To further increase the number of segments and 
of different views for analysis, ahigh number of 
different axial and half-axial angiographic pro- 
jections (eventually with recommendation of
definite projection angles) should be mandatory 
in future coronary angiographic follow-up trials 
with quantitative geometrical cinefilm analysis. 
7. The double-blind feature of studies like IN- 
TACT is essential to allow for conclusive results 
despite numerous limitations of the present 
methods. 
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Appendix 
Centers participating in INTA CT 
Germany: 
1. Medizinische Hochschule Hannover 
PR Lichtlen, W Raffienbeul, SJost, P Nikutta, U Neltessen, 
B Schneider, H Hecker, B Wiese 
2. Universit~itsklinikum Eppendorf, Hamburg 
W Bleifeld, C Harem, W Kupper 
3. Zentralkrankenhans 'Links der Weser', Bremen 
HJ Engel, H Werner 
4. Universit~tsklinik Charlottenburg, Berlin 
H Schmutzler, H Bias 
5. Universitgtsklinikum Frankfurt 
M Kaltenbach, G Kober, H Klepzig, D Kneissl 
6. Medizinische Poliklinik der Universitfit Erlangen 
K Bachmann, S Haetinger 
The Netherlands: 
7. Academisch Ziekenhuis Dijkzigt, Thoraxcentrum Rotterdam 
PG Hugenholtz, JW Deckers, JHC Reiber, K Laird-Meeter, 
PW Serruys 
8. Catharina-Hospital, Eindhoven 
JJRM Bonnier, RHR Miehets, J Troquay 
9. Academisch Ziekenhuis Groningen 
KI Lie, ED De Muinck, J Posma 
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